Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Mega Mergers: Is Bigger Really Better?

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck, Wyeth execs say large-scale mergers are indeed necessary to compete in pharma R&D and maintain global reach cost effectively.

You may also be interested in...

Get Ready For The Return Of The Mega-Merger, Leerink Says

Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.

Lilly Plays Up R&D Productivity With Reorganization

Teetering on the brink of a vast patent cliff, Eli Lilly announced a reorganization and cost-cutting initiative Sept. 14. The program - intended to cut $1 billion in costs by the end of 2010 - is as much about enhancing R&D productivity as creating a leaner organization, according to the company

Pfizer Restructures For A More Flexible Future

In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care and emerging markets





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts